Background. Nephronophthisis (NPHP), the most frequent genetic cause of end-stage kidney disease in children and young adults, is characterized by a variable number of renal cysts associated with cortical tubular atrophy and interstitial fibrosis. The p38 mitogen-activated protein kinase (MAPK) pathway is an important intracellular signaling pathway involved in the production of profibrotic mediators. The relationship between p38 MAPK and renal fibrosis in NPHP2 is unknown. Methods. We administered a selective p38 MAPK inhibitor, FR167653, in a NPHP2 mouse model (inv/inv, invDC mice) from 3 to 6 weeks old, and the kidneys were examined at 6 weeks of age. Phosphorylation of p38 MAPK (p-p38 MAPK) protein levels, the degree of renal fibrosis, messenger RNA (mRNA) levels for extracellular matrix genes and mRNA levels for transforming growth factor in the kidneys were studied. Effect of an extracellular signal-regulated protein kinase (ERK) kinase (MEK) inhibitor on renal fibrosis was also evaluated. Results. Expression of extracellular matrix genes and p-p38 MAPK were increased in the NPHP2 mouse model kidney. FR167653 successfully decreased p-p38 MAPK levels, the degree of fibrosis and extracellular matrix gene expressions. However, the FR167653 did not prevent cyst expansion, abnormal cell proliferation and acceleration of apoptosis and did not influence ERK activation. In contrast, MEK inhibition reduced both cyst expansion and fibrosis without affecting p38 MAPK activation. Conclusions. These results suggest that inhibition of p38 MAPK reduced renal fibrosis but not cyst expansion, cell proliferation and apoptosis in NPHP2 model mice. Our results suggest that p38 MAPK and ERK signaling pathways independently affect renal fibrosis in inv mutant mice.
Introduction
Nephronophthisis (NPHP) is a genetic disorder of the kidney that affects children [1] . The disorder is inherited in an autosomal recessive fashion and is the most common genetic cause of childhood renal failure [2] . Eleven genes responsible for NPHP have been identified [3] . Characteristic features of NPHP are renal fibrosis and cyst formation [4] . Fibrosis is the deposition of collagen and other extracellular matrix (ECM) components in tissue. Pcy mutant mice, which carry a mutation in the nphp3 gene, is reported to show renal fibrosis and over-express ECM-related genes including collagen a1 (I), a1 (III) and a1 (IV) with cyst progression [5, 6] . Over-expression of many ECM-related genes has also been reported in advanced cyst stages in other animal renal cyst models [7] [8] [9] . The epithelialmesenchymal transition (EMT) is known to play a role in renal fibrosis in ischemia-reperfusion injury. Previous reports showed that 36% of new fibroblasts originated from local EMT and that 15% were from bone marrow, the rest being local proliferation [10] . EMT was observed in human and mouse polycystic kidney disease [11] [12] [13] [14] [15] [16] .
The infantile form of NPHP (NPHP type 2) is caused by mutation in the human Invs/NPHP2 gene, which has been identified as the mouse inv gene homolog [17] . The inv gene was first discovered as the gene responsible for the mouse inv mutant [18] . The inv mouse shows a reversal of left-right asymmetry, jaundice and multiple renal cysts and mimics a phenotype in human infantile NPHP2 [19, 20] . Most inv mutant mice die before 7 days of age. The inv/inv, invDC::green fluorescent protein (GFP) (invDC) mouse was created by introduction of an inv gene that lacked a C-terminus fused with GFP into an inv mutant mouse [21] . The inv/inv, invDC mouse develops renal cysts, but it does not show any situs abnormalities or jaundice and can survive beyond 6 weeks of age [22] . Since renal cysts grow slowly in this mouse, inv/inv, invDC mice are suitable for investigating the mechanisms for development of cystic kidney disease.
The mitogen-activated protein kinase (MAPK) family of serine/threonine kinase includes extracellular signalregulated protein kinase (ERK), p38 MAPK and c-Jun N-terminal kinase (JNK), which have been reported to be activated in human and mouse cystic kidneys [23] [24] [25] [26] . In inv mutant mice, ERK and p38 MAPK are activated in an early phase of cyst development, and JNK is activated in a late phase of cyst development [27] . We previously reported that inhibition of the ERK signaling pathway resulted in inhibition of renal cyst enlargement and cell proliferation in inv mutant mice [27] . The p38 MAPK pathway and transforming growth factor (TGF)-b signaling are important intracellular signal transduction pathways for fibrosis, and previous reports have shown that pharmacological inhibition of p38 MAPK has beneficial effects in various animal models involving inflammatory disorders [28, 29] and obstructive nephropathy [30, 31] .
In the present report, we determined if the p38 MAPK pathway affects renal cyst and fibrosis in inv mutant mice. We examined p38 MAPK activation in the inv/inv, invDC cystic kidney and then treated inv/inv, invDC mice with a selective p38 MAPK inhibitor, FR167653.
Materials and methods

Animals
The experimental protocols were performed according to the regulations of the Medicine Animal Care Committee of Kyoto Prefectural University. We used inv/inv, invDC mice in this study. The inv/inv, invDC mice used in this study were inv/inv mice carrying two alleles of invDC transgenes [22, 27] .
FR167653 and PD184352 treatment protocol
A selective p38 MAPK inhibitor, FR167653 (Astellas Pharma Inc., Tokyo, Japan), was injected subcutaneously once a day at a dose of 33 mg/kg body weight diluted in 0.5% methylcellulose in phosphate-buffered saline (PBS) from 3 to 6 weeks of age [32, 33] . A control group was injected with vehicle (0.5% methylcellulose in PBS). Inv/inv, invDC mice treated with FR167653 (n ¼ 23) and vehicle (n ¼ 15) as well as control 1/1, invDC mice treated with FR167653 (n ¼ 6) and vehicle (n ¼ 6) were analyzed at 6 weeks of age. Administration of PD184352 as an oral MEK inhibitor was previously described [27, 34] . No difference was observed in survival rate between FR16735 and vehicle-treated groups as well as non-treated inv/inv, invDC mice group (supplementary table) . Inv/inv, invDC mice treated with PD184352 (n ¼ 3) and vehicle (n ¼ 3) were subject for analysis.
Histological analysis
For morphological evaluation, kidneys were fixed in 4% paraformaldehyde in PBS for 8 h and embedded in paraffin wax. Sections (4 lm thick) were stained with hematoxylin and eosin stain and Heidenhain azan stain according to standard protocols.
Immunohistochemical staining for phospho-p38 (p-p38) MAPK was performed on frozen sections. Kidney samples for p-p38 MAPK staining were frozen in liquid nitrogen into Tissue Tek OCT compound (Sakura Finetechnical Co. Ltd. Tokyo, Japan) and stored at À30°C until sectioned. Sections were cut at 10 lm and fixed in 4% paraformaldehyde in PBS at room temperature for 20 min monoclonal rabbit anti-p-p38 MAPK antibody (dilution 1:1,000, #9211; Cell Signaling Technology Inc, Beverly, MA).
Apoptotic cell number was assayed using the terminal deoxynucleotidyl transferase dUTP nick end labeling method as previously described [10] . We examined at least 1000 renal tubular epithelium cells in kidneys from the control (n ¼ 6) and FR167653-treated groups (n ¼ 6).
Measurement of the fibrosis index
The fibrosis index was determined as a percentage of aniline blue staining area by Heidenhain azan staining, according to the method by Ma et al. [35] . Using Photoshop 7.0 for Macintosh (Adobe Systems, San Jose, CA) and ImageJ software (National Institutes of Health, Bethesda, MD), the aniline blue-stained fractional pixels to total pixels ratio was determined in Heidenhain azan-stained sections. Under high magnification of a 340 objective, 20 consecutive non-overlapping fields of renal cortex and medulla in each kidney [at least 1500 fields, in vehicle (n ¼ 12) and FR167653 (n ¼ 16) treated inv/inv, invDC mice] were observed. After data acquisition, raw images were opened with Photoshop 7.0 and images were processed with the built-in adjustments function of 'auto levels', 'auto contrast' and 'auto color'. No further image manipulation was performed. The data was separated by the RGB color channels and the Blue channel was used to determine the blue stained area. Blue stained area pixels and total area pixels were measured by ImageJ software. The fibrosis index showed the percentage of blue pixels to total pixels. Glomeruli, Bowman's capsules, vessels, tubular basal membrane and the interstitial tissue were assessed for the amount of fibrosis in these protocols.
Sircol collagen assay
Kidneys were homogenized in 0.5M acetic acid containing 0.1 mg/mL pepsin (Sigma-Aldrich Japan, Tokyo, Japan). Each sample was incubated for 24 h at 4°C with stirring. After centrifugation, the total of each supernatant was neutralized and treated by isolation and concentration reagent for 24 h at 4°C. After centrifugation, each precipitation was assayed. One milliliter of Sircol dye reagent which specifically binds to collagen was then added to each sample and mixed for 30 min. After centrifugation, the pellet was suspended in 1 mL of alkali reagent (0.5 M NaOH) included in the kit and optical density evaluated at 540 nm with a spectrophotometer. The values in the test samples were compared to the values obtained with collagen standard solutions provided by the manufacturer that were used to construct a standard curve. Control (1/1, invDC, n ¼ 7) and inv/inv, invDC (n ¼ 10) were analyzed. Vehicle-treated (n ¼ 10) and FR167653-treated (n ¼ 13) inv/inv, invDC mice were analyzed.
Immunoblot analysis
Western blot analysis was performed as previously described [22] . The antibodies used were polyclonal rabbit anti-p38 MAPK (dilution 1:1,000, #9212; Cell Signaling Technology Inc.), polyclonal rabbit anti-p-p38 MAPK (Thr180/Tyr182) (dilution 1:1,000, #9211; Cell Signaling Technology Inc.), anti-actin (dilution 1:200, sc-1616; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and anti-proliferating cell nuclear antigen [(PCNA), dilution 1:500, VP-P980; Vector Laboratories, Inc., Burlingame, CA].
In p-p38 MAPK immunoblot analysis, we examined one every nine kidneys on time-course experiment of inv/inv, invDC mice, all kidneys on FR167653 administration experiment and one in every three kidneys on PD184352 treatment. In PCNA analysis, we examined one in every six kidneys of all groups. In ERK analysis, we examined three kidneys of all groups.
Biochemical analysis
Blood samples were obtained by cardiac puncture in all 6-week-old mice of administration experiment groups. Blood urea nitrogen (BUN) and serum creatinine (Cre) concentrations were measured by Mitsubishi Kagaku Bio-Clinical Laboratories.
Real-time reverse transcription-polymerase chain reaction analysis
Real-time reverse transcription-polymerase chain reaction (PCR) was carried out on an Applied Biosystems 7300 real-time PCR system (Foster City, CA). Glyceraldehyde 3-phosphate dehydrogenase (gapdh) was used as the control gene for normalization. Each primer is shown in Table 1 . One in every five kidneys were examined for collagen genes in all groups of time-course experiment of inv/inv, invDC mice and in all groups of FR167653 administration experiment. One in every three kidneys were examined for collagen genes in all groups of PD184352 administration experiments. TGF-ß1 levels were measured in five kidneys in all groups of time-course experiment and three kidneys in all groups of FR167653 administration experiment.
Statistical analysis
Data are expressed as mean AE SE. Comparison of the data between the two groups was performed using an unpaired t-test as appropriate. Multiple group comparison of the data was performed using one-way analysis of variance with post-hoc Tukey-Kramer test. Survival rate was derived using the Kaplan-Meier method and was compared using log-rank test. Statistical analysis was performed using Excel (Microsoft, Redmond, WA) and Statcel 2 plug-in software (OMS Publishing, Saitama, Japan).
Results
Collagen gene expression and p38 MAPK activation in cystic kidneys of invDC mice Expression levels of all collagen genes at 1 week of age were similar between control (1/1, invDC) and inv/inv, invDC kidneys ( Figure 1A ). Expression levels of Col1a1 and Col3a1 in inv/inv, invDC cystic kidneys were significantly higher at 3 and 6 weeks of age compared with those in controls. Expression levels of Col4a1 in inv/inv, invDC cystic kidneys were similar to those in controls at 3 weeks of age, but they were significantly higher at 6 weeks of age compared with those in controls. Sircol collagen assay confirmed that the collagen content ratio in inv/inv, invDC cystic kidneys at 6 weeks of age (1 AE 0.07) was significantly higher than that of control 1/1, invDC (6.4 AE 0.47), P < 0.01 ( Figure 1C) .
The total amount of p38 MAPK protein was not different between control (1/1, invDC) and inv/inv, invDC kidneys at all examined ages ( Figure 1B) . Phosphorylated p38 MAPK of inv/inv, invDC kidneys was significantly higher in 3-week-old (P < 0.05) and 6-week-old (P < 0.01) mice compared with that in controls ( Figure 1B) . Intense p-p38 MAPK signals were detected by immunohistochemical staining of renal tissue in tubular epithelial cells of renal cysts in 6-week-old inv/inv, invDC kidneys ( Figure 1D ).
FR167653 decreases p38 MAPK phosphorylation but does not influence renal cyst progression, kidney function marker levels, cell proliferation and apoptosis FR167653 and vehicle treatment did not affect p-p38 MAPK levels in 1/1, invDC kidneys (Figure 2A and B) . FR167653 treatment decreased p-p38 MAPK levels in inv/ inv, invDC kidneys compared with those in vehicle-treated inv/inv, invDC kidneys (Figure 2A and B) . The amount of p-p38 MAPK in FR167653 treated inv/inv, invDC kidneys was reduced to the almost identical level of that in controls (1/1, invDC kidney with or without FR167653). However, FR167653 administration failed to reduce the kidney size of inv/inv, invDC mice ( Figure 2C ). There was no difference in the kidney weight to body weight ratio ( Figure 2D ) and the distribution of tubular sizes ( Figure 2E -G) between FR167653-treated (n ¼ 23) and vehicle-treated (n ¼ 15) inv/inv, invDC mice. Cre and BUN concentrations of FR167653-treated inv/inv, invDC mice were similar to those in the controls ( Figure 2H ). Furthermore, cell proliferation and apoptosis of FR167653-treated inv/inv, invDC mice were not different to those in controls ( Figure 2I and J) . Most of the cell proliferation and apoptosis were observed in renal tubular epithelial cells in inv/inv, invDC kidney [22] . Thus, inhibition of the p38 MAPK signal did not influence cyst progression, cell proliferation and apoptosis of inv/inv, invDC kidneys.
Effect of FR167653 treatment on renal fibrosis and TGF-ß1 expression in inv/inv, invDC cystic kidneys
We then examined FR167653 treatment in inhibiting renal fibrosis. Treatment with FR167653 resulted in a significant decrease in the fibrosis index in inv/inv, invDC kidneys (n ¼ 12) at 6 weeks of age compared with that of the vehicle-treated group (n ¼ 16) (43 AE 4.47 versus and inv/inv, invDC groups are indicated by the white and black bars, respectively. Results are expressed as a ratio of the density of p-p38 MAPK to total p38 MAPK. The obtained values were further compared with the mean value from 1-week-old control mice (*P < 0.05 and **P < 0.01 compared with controls of the same age, all groups were n ¼ 9). (C) Sircol collagen assay in 6-week-old kidney. Results are expressed as a total collagen content/wet tissue weight. The obtained values were further compared with mean value from 6-week-old control mice (*P < 0.01 compared with control). (D) Immunohistochemical staining of p-p38 MAPK in 6-week-old inv/inv, invDC kidneys (right) and controls (1/1, invDC) (left).
p38 induces fibrosis in NPHP2 kidneys 28.7 AE 4.27%, P < 0.01) ( Figure 3A and B). Treatment with FR167653 resulted in a significant decrease in mRNA expression for the three collagen genes (Col1a1, Col3a1 and Col4a1) compared with that in vehicle-treated groups ( Figure 3C ). Further, treatment with FR167653 resulted in a significant decrease in the total collagen content in inv/ inv, invDC kidneys at 6 weeks of age compared with that of the vehicle-treated group by Sircol collagen assay (6.4 AE 0.47 versus 4.0 AE 0.03, P < 0.01) ( Figure 3D ). TGF-b1 mRNA expression levels were not different between 1/1, invDC and inv/inv, invDC kidneys at 1 week of age. Expression levels of TGF-b1 in inv/inv, invDC kidneys started to increase from 3 weeks old and were significantly higher at 6 weeks old compared with those in age matched 1/1, invDC controls (P < 0.01) ( Figure 3E ). However, treatment with FR167653 did not affect TGF-b1 mRNA levels at any age ( Figure 3F ).
Effect of PD184352 treatment on renal fibrosis in inv/ inv, invDC cystic kidneys Finally, we examined if MEK inhibition affects p38 activation and fibrosis. We have previously shown that the blockage of ERK pathway by PD184352, a MEK inhibitor, reduced cell proliferation and cyst formation in inv/inv, invDC mice [27] . Treatment with PD184352 resulted in a significant decrease in the fibrosis index in inv/inv, invDC kidneys at 6 weeks of age compared with that of the vehicle-treated group (40.3 AE 2.13 versus 28.1 AE 2.38%, P < 0.01, n ¼ 3 in controls and the PD184352-treated group) ( Figure 4A and Supplementary figure 1). Treatment with PD184352 resulted in a significant decrease in mRNA expression for the two collagen genes (Col1a1 and Col3a1) compared with that in vehicle-treated groups except Col4a1 ( Figure 4B ). PD184352 did not affect p38 MAPK phosphorylation ( Figure 4C ) and FR167653 did not affect ERK phosphorylation ( Figure 4D ).
Discussion
FR167653 reduced the high p-p38 MAPK/p38 MAPK ratio and renal fibrosis in inv/inv, invDC kidneys to control levels. The p38 MAPK-activated cells were tubular epithelial cells. It has been reported that activation of p38 MAPK makes renal epithelial cells express smooth muscle actin (SMA) [36, 37] . In the present study, SMA-positive cells were observed not only in the fibrotic area but also in cyst lining cells (Supplementary figure 2) , although the number of positive cells is low. In vitro studies have shown that TGF-b1 increases activation of p38 MAPK, which induces EMT in renal epithelial cells [36, 37] . Our results showed that TGF-b1 mRNA expression levels were increased in inv/inv, invDC kidneys. However, TGF-b1 expression levels were not affected by administration of FR167653. Thus, p38 MAPK is likely to act on downstream signaling of TGF-b1 in renal fibrosis in the inv cystic kidney. Our studies suggested that EMT of tubular cells contributed the fibrosis at least in this particular NPHP mouse model. However, recent reports showed that renal epithelial cells did not become myofibroblasts in vivo [38] and that pericytes and perivascular fibroblasts were the primary source of collagen-producing cells [39] . We do not deny a possibility that p38 MAPK may induce secretion of some fibrogenic cytokines from renal tubular cells and induce activation of collagen producing cells in inv cystic kidney. The obtained values were further compared with mean value from 6-week-old vehicle-treated 1/1, invDC kidneys (*P < 0.01). (E) Quantitative analysis of TGF-b1 mRNA expression levels in inv/inv, invDC (black bar) and 1/1, invDC mice (white bar). The obtained values were compared with the mean value from 1/1, invDC mice at same age (*P < 0.01 compared with 1/1, invDC of the same age). Error bar ¼ SE (F) Comparison of TGF-b1 mRNA expression in FR167653 (black bar) and vehicle-treated (white bar) invDC kidneys. The obtained values were compared with the mean value from vehicle mice of the same age. Error bar ¼ SE Although FR167653 treatment effectively inhibited p38 MAPK activation and renal fibrosis, it did not inhibit the increase in kidney weight, expansion in renal tubules, cell proliferation and apoptosis in renal epithelial cells. Thus, intracellular signaling pathways that induce cell proliferation, apoptosis and cyst formation were p38 MAPK independent. We previously reported that small cysts were already found in some inv/inv, invDC mice at 1 week of age, and that all the inv/inv, invDC mice at 3 weeks of age had many enlarged renal cysts [27] . The present results showed that collagen a1 (I), a1 (III) and a1 (IV) gene expression was increased after cyst development in inv/inv, invDC kidneys, suggesting that renal fibrosis develops after cyst formation.
Inhibition of fibrosis by FR167653 treatment reduced fibrosis~60% of vehicle control but not complete. The results suggest that there are other pathways to induce renal fibrosis in inv/inv, invDC kidneys. PD184352, a MEK inhibitor, suppressed both renal cyst and fibrosis and ameliorated renal function [27] . FR167653 treatment did not alter ERK activation. Conversely, PD184352 did not affect p38 MAPK activation. These results suggest that both p38 MAPK and ERK pathways are likely to be independently involved in renal fibrosis of inv/inv, invDC mice.
Reduction of fibrosis with FR167653 had no effect on renal function and survival rate in our study. Although reduction of fibrotic index with PD184352 treatment (12.2%) was lower than that with FR167653 treatment (19.2%), we (B) Quantitative analysis of three collagen mRNA expression levels. P < 0.01, Error bar ¼ SE (C) Immunoblot analysis of p-p38 MAPK and total p38 MAPK proteins of vehicle-treated and PD184352-treated 1/1, invDC and inv/inv, invDC mice. Right graph is densitometric quantitation of three independent immunoblots. Results are expressed as a ratio of the density of p-p38 MAPK to total p38 MAPK. The obtained values were further compared with the mean value from vehicle-treated 1/1, invDC mice (*P < 0.01). (D) Immunoblot analysis of phospho-ERK and total ERK proteins of vehicletreated and FR167653-treated 1/1, invDC and inv/inv, invDC mice. Right graph is densitometric quantitation of three independent immunoblots. Results are expressed as a ratio of the density of phospho-ERK to total ERK. The obtained values were further compared with the mean value from vehicletreated 1/1, invDC mice (*P < 0.01).
had observed improvement in renal functions of PD184352-treated group [27] . These results suggest that renal fibrosis in inv/inv, invDC mice is not an important factor for renal function. Renal volume was reported to be inversely correlated to renal function in autosomal polycystic kidney disease [40] . Therefore, suppression of the cyst expansion but not fibrosis may be important for improvement of renal function in inv/inv, invDC mice.
In summary, the present results support that the primary lesion of the inv/inv, invDC mutant kidney is located in renal epithelial cells and that interstitial fibrosis is a secondary manifestation. Although both ERK and p38 MAPK signaling pathways are activated in an early phase of cyst formation, the two pathways have different roles in the inv kidney. Activation of ERK contributes to cyst expansion as well as to fibrosis, cell proliferation and apoptosis, whereas activation of p38 MAPK signaling promotes renal fibrosis only.
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